ArQule, Inc. (ARQL) Receives $6.75 Consensus PT from Analysts
ArQule, Inc. (NASDAQ:ARQL) has earned a consensus recommendation of “Buy” from the eight analysts that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $6.75.
A number of equities analysts have recently commented on the company. BidaskClub downgraded ArQule from a “buy” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research downgraded ArQule from a “buy” rating to a “hold” rating in a research report on Friday, August 10th. B. Riley set a $7.00 price objective on ArQule and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Finally, ValuEngine downgraded ArQule from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 31st.
NASDAQ:ARQL traded up $0.06 on Friday, reaching $5.10. 19,915 shares of the company’s stock were exchanged, compared to its average volume of 905,321. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.99 and a quick ratio of 5.99. The firm has a market capitalization of $595.23 million, a PE ratio of -13.00 and a beta of 1.01. ArQule has a 52-week low of $0.97 and a 52-week high of $7.21.
Several institutional investors have recently made changes to their positions in ARQL. Jane Street Group LLC acquired a new position in shares of ArQule during the first quarter worth about $100,000. CAPROCK Group Inc. acquired a new position in ArQule in the second quarter valued at approximately $109,000. Zebra Capital Management LLC acquired a new position in ArQule in the second quarter valued at approximately $115,000. Millennium Management LLC acquired a new position in ArQule in the fourth quarter valued at approximately $165,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in ArQule in the second quarter valued at approximately $169,000. 65.10% of the stock is owned by institutional investors and hedge funds.
ArQule Company Profile
ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. It offers Derazantinib (ARQ 087), a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family that is in a registration trial in intrahepatic cholangiocarcinoma with FGFR2 fusions.
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.